Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Search PHGKB:

Last Posted: May 28, 2023
spot light Highlights

Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice.
Jacques Raphael et al. J Natl Cancer Inst 2023 5

A total of 7,126 patients treated with ICI were evaluated. Fifteen percent (1,075/7,126) died within 60?days of initiating ICI. The highest mortality was observed in patients with bladder and head and neck tumors (˜21% each). In multivariable analysis previous hospital admission or emergency department visit, prior chemotherapy or radiation therapy, stage 4 disease at diagnosis, lower hemoglobin, higher white blood cell count, and higher symptom burden were associated with higher risk of EM.

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
MW Lucas et al, Nat Rev Clin Oncol, May 2023

Neoadjuvant immune-checkpoint inhibition is a promising emerging treatment approach for patients with surgically resectable macroscopic stage III melanoma. The neoadjuvant setting provides an ideal platform for personalized therapy owing to the very homogeneous nature of the patient population and the opportunity for pathological response assessments within several weeks of starting treatment, thereby facilitating the efficient identification of novel biomarkers.

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
Charu Aggarwal et al. JAMA Netw Open 2023 5 (5) e2311181

Is a tumor mutational burden (TMB) biomarker associated with clinical benefit in a cohort of patients with advanced cancer from diverse clinical settings treated with first- or second-line immune checkpoint inhibitors (ICI)? In this cohort study of 674 patients with 8 distinct advanced cancer diagnoses, TMB-high cancers were significantly associated with longer overall survival than TMB-low cancers. These findings were robust to the ICI administered and remained significant after adjustment for programmed cell death-ligand 1 and microsatellite instability status.

Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
K Chamoto et al, Nat Rev Immunology, April 2023

PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding overactivation-induced cell death and autoimmunity, whereas its inhibition unleashes anticancer immunity. Here, we outline the journey from the discovery of PD1 to its role as a breakthrough target in cancer immunotherapy.

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.